<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04129320</url>
  </required_header>
  <id_info>
    <org_study_id>CP-MGA271-05</org_study_id>
    <nct_id>NCT04129320</nct_id>
  </id_info>
  <brief_title>Enoblituzumab Plus MGA012 in Squamous Cell Carcinoma of the Head and Neck</brief_title>
  <official_title>A Phase 2/3 Open-Label Trial to Evaluate Enoblituzumab in Combination With MGA012, With and Without Chemotherapy, in the First-Line Treatment of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MacroGenics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MacroGenics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2/3, randomized, open-label study designed to evaluate safety and efficacy of
      enoblituzumab in combination with MGA012, with and without chemotherapy, in first-line
      treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and
      neck (SCCHN). The study will be conducted in 2 modules, Module A (Phase 2) and Module B
      (Phase 3).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In Module A, approximately 200 patients will be randomized to 1 of 4 arms (approximately 50
      patients each arm): pembrolizumab + chemotherapy, enoblituzumab + MGA012, enoblituzumab +
      MGA012 + chemotherapy, and MGA012 + chemotherapy. Data from the enoblituzumab + MGA012 arm
      and enoblituzumab + MGA012 + chemotherapy arm will be assessed to determine whether further
      evaluation of one of these arms in Module B is warranted. If one or more of the experimental
      arms demonstrates improved efficacy with acceptable safety compared to the pembrolizumab +
      chemotherapy arm, enrollment will be initiated in Module B with approximately 260 patients
      per arm (enoblituzumab + MGA012 with or without chemotherapy vs. pembrolizumab +
      chemotherapy).
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2019</start_date>
  <completion_date type="Anticipated">October 2025</completion_date>
  <primary_completion_date type="Anticipated">October 2025</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate - Module A</measure>
    <time_frame>2 years</time_frame>
    <description>Proportion of patients with best overall response of complete response (CR) plus partial response (PR) per RECIST 1.1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Adverse Events as assessed by CTCAE v 4.03 - Module A and B</measure>
    <time_frame>Up to 30 days after last dose of study drug</time_frame>
    <description>Evaluation of adverse events and serious adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival - Module A and B</measure>
    <time_frame>2 years</time_frame>
    <description>Time from randomization to death from any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity - Module A</measure>
    <time_frame>2 years</time_frame>
    <description>Percentage of patients developing anti-drug antibodies to enoblituzumab and/or MGA012</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival - Module A and B</measure>
    <time_frame>2 years</time_frame>
    <description>Time from start of study treatment to the first documented disease progression per RECIST v1.1 or death due to any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate - Module A and B</measure>
    <time_frame>2 years</time_frame>
    <description>Percentage of patients who experienced response of CR, PR or stable disease for at least 3 months from start of study treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response - Module A and B</measure>
    <time_frame>2 years</time_frame>
    <description>Time from the date of initial response to the date of first documented progression or death from any cause, whichever occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life QLQ-C30 - Module B</measure>
    <time_frame>2 years</time_frame>
    <description>EORTC overall Quality of Life questionnaire QLQ-C30 on a scale of 0-100. Lower scores correlate with worse quality of life and higher scores correlate with better quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life H&amp;N-35 - Module B</measure>
    <time_frame>2 years</time_frame>
    <description>EORTC Quality of Life questionnaire H&amp;N-35 for head and neck cancer patients on a scale of 0-100. Lower scores correlate with worse quality of life and higher scores correlate with better quality of life.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">750</enrollment>
  <condition>Head and Neck Cancer</condition>
  <condition>Squamous Cell Carcinoma of Head and Neck</condition>
  <arm_group>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pembrolizumab plus Chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enoblituzumab plus MGA012</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enoblituzumab plus MGA012 plus Chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental Arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MGA012 plus Chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>pembrolizumab</intervention_name>
    <description>anti-PD-1 antibody</description>
    <arm_group_label>Control Arm</arm_group_label>
    <other_name>Keytruda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>enoblituzumab</intervention_name>
    <description>anti-B7-H3 antibody</description>
    <arm_group_label>Experimental Arm 1</arm_group_label>
    <arm_group_label>Experimental Arm 2</arm_group_label>
    <other_name>MGA271</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MGA012</intervention_name>
    <description>anti-PD-1 antibody</description>
    <arm_group_label>Experimental Arm 1</arm_group_label>
    <arm_group_label>Experimental Arm 2</arm_group_label>
    <arm_group_label>Experimental Arm 3</arm_group_label>
    <other_name>INCMGA00012</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapeutic Combinations</intervention_name>
    <description>carboplatin or cisplatin plus 5-fluorouracil (5-FU)</description>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_label>Experimental Arm 2</arm_group_label>
    <arm_group_label>Experimental Arm 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven, recurrent or metastatic SCCHN not curable by local therapy

          -  No prior systemic therapy for SCCHN in the recurrent or metastatic setting (with the
             exception of systemic therapy completed &gt; 6 months prior of given as part of
             multimodal treatment for locally advanced disease)

          -  Primary tumor locations of oropharynx, oral cavity, hypopharynx, or larynx

          -  HPV test results available (positive and negative eligible)

          -  ECOG Performance status of 0 or 1

          -  Adequate end organ function

        Exclusion Criteria:

          -  Progressive disease within 6 months of completion of curatively intended systemic
             treatment for locoregionally advanced SCCHN

          -  Radiation or other non-systemic therapy within 2 weeks of randomization

          -  Diagnosis of immunodeficiency, or use of immunosuppresive therapy within 14 days of
             first dose of study drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fernanda I Arnaldez, MD</last_name>
    <role>Study Director</role>
    <affiliation>MacroGenics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Susan Brann</last_name>
    <phone>240-552-8023</phone>
    <email>branns@macrogenics.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Scott Currence</last_name>
    <phone>240-552-8081</phone>
    <email>currences@macrogenics.com</email>
  </overall_contact_backup>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 14, 2019</study_first_submitted>
  <study_first_submitted_qc>October 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 16, 2019</study_first_posted>
  <last_update_submitted>October 15, 2019</last_update_submitted>
  <last_update_submitted_qc>October 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SCCHN</keyword>
  <keyword>head and neck</keyword>
  <keyword>oropharyngeal</keyword>
  <keyword>oral cavity</keyword>
  <keyword>hypopharyngeal</keyword>
  <keyword>laryngeal cancer</keyword>
  <keyword>immunotherapy</keyword>
  <keyword>PD-1</keyword>
  <keyword>B7-H3</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

